Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)
reasanz
novartis europharm ltd - serelaxin - Širdies nepakankamumas - kiti vasodilators naudojamas širdies ligų - Ūmių širdies nepakankamumas.
![Molsidominum PPH [MOLSIDOMINUM WZF Polfa]](/web/assets/global/img/flags/lt.png){kind=small}
Lietuva -
lietuvių -
SMCA (Valstybinė vaistų kontrolės tarnyba)
molsidominum pph [molsidominum wzf polfa]
zakłady farmaceutyczne polpharma s.a. - molsidominas - tabletės - 4 mg; 2 mg - molsidomine
Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)
nuceiva
evolus pharma b.v. - a tipo botulino toksinas - odos senėjimo - kitos raumenų relaxants, periferijoje veikiantys agentai - laikino pagerėjimo išvaizdos, vidutinio sunkumo ir sunkią vertikalių linijų tarp antakių pamatyti didžiausią raukytis (glabellar eilutės), kai sunkumas virš veido linijas yra svarbus psichologinis poveikis suaugusiesiems, vyresniems kaip 65 metų amžiaus.
Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)
sugammadex mylan
mylan ireland limited - sugammadex sodium - neuromuskulinė blokada - visi kiti gydomieji produktai - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)
sugammadex fresenius kabi
fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskulinė blokada - visi kiti gydomieji produktai - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)
sugammadex piramal
piramal critical care b.v. - sugammadex sodium - neuromuskulinė blokada - sugamadeksas - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
Lietuva -
lietuvių -
SMCA (Valstybinė vaistų kontrolės tarnyba)
sugammadex kalceks
as kalceks - sugamadeksas - injekcinis tirpalas - 100 mg/ml - sugammadex
Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)
bimzelx
ucb pharma s.a. - bimekizumab - psoriazė - imunosupresantai - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.